
Genitourinary Cancers
Latest News
Latest Videos

Shorts










Podcasts
CME Content
More News

Patients who developed ototoxicity during cisplatin treatment experienced less worsening of pure-tone audiometry thresholds in ears treated with ACOU085 compared with placebo-treated ears.

A recap of the FDA submissions and regulatory decisions in urology from April 2026.



In this first installment of a 2-part interview, guideline chair professor Axel Heidenreich outlines key updates in the management of testicular cancer, with a strong focus on deintensification.

The assay is designed to detect multiple cancers, including prostate, bladder, and kidney cancer, through a simple, non-invasive urine sample.

The phase 2 PROHEAR trial is assessing the safety and efficacy of ACOU085 in preventing ototoxic hearing loss induced by cisplatin-based chemotherapy.

Joshua Palka, DO, reflects on the key trends that shaped urologic oncology in 2025, emphasizing the growing role of precision medicine across disease states.

The subcutaneous formulation of pembrolizumab also received FDA approval in September 2025.

The approval is supported by data from the phase 3 MK-3475A-D77 trial.

Take a look through key stories from last month, including regulatory news, trial updates, and other practice-changing advancements.

The findings highlight a lack of awareness on the signs and symptoms of prostate cancer, as well as common misconceptions about testicular cancer.

"Pediatric-type cancer diagnoses in adults are rare, and there are important differences in caring for children with genitourinary malignancies compared with adults," write the authors.























